Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Li, Jing ^a,b   Wang, Qian ^a   Chai, Weidong ^c   Chen, Mei Hua ^a   Liu, Zhenqi ^c   Shi, Weibin ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b TIANJIN UNIVERSITY   (China)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CYTOKINE; AUTACOID; BIOLOGICAL MARKER; GALECTIN 3; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEEDING; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; MACROPHAGE; MICROSCOPY; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PROTEIN MICROARRAY; ANIMAL; AORTA DISEASE; BLOOD; C57BL MOUSE; DISEASE MODEL; GENETICS; INSULIN RESISTANCE; LIPID DIET; METABOLISM; MOUSE MUTANT; PATHOLOGY; SPECIES DIFFERENCE; TIME;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GALECTIN 3; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN ARRAY ANALYSIS; SPECIES SPECIFICITY; TIME FACTORS;

EID: 84455193306     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-117     Document Type: Article

References (42)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234. 10.1056/NEJM199807233390404, 9673301.
2. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM. The evolving diabetes burden in the United States. Ann Intern Med 2004, 140(11):945-950.
3. Bloomgarden ZT. Insulin resistance, dyslipidemia, and cardiovascular disease. Diabetes Care 2007, 30(8):2164-2170. 10.2337/dc07-zb08, 17855278.
4. Ruderman NB, Haudenschild C. Diabetes as an atherogenic factor. Prog Cardiovasc Dis 1984, 26(5):373-412. 10.1016/0033-0620(84)90011-2, 6371895.
5. Bloomgarden ZT. Cardiovascular disease in diabetes. Diabetes Care 2008, 31(6):1260-1266. 10.2337/dc08-zb06, 18509144.
6. Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep 2008, 8(1):51-59. 10.1007/s11892-008-0010-5, 18366999.
7. Verges B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009, 23(6):681-685. 10.1111/j.1472-8206.2009.00739.x, 19650852.
8. von Eckardstein A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Munster. J Clin Endocrinol Metab 2000, 85(9):3101-3108. 10.1210/jc.85.9.3101, 10999793.
9. Kendall DM. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?. Endocrinol Metab Clin North Am 2005, 34(1):27-48. 10.1016/j.ecl.2004.11.004, 15752920.
10. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347(19):1483-1492. 10.1056/NEJMoa020194, 12421890.
11. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109(18):2197-2202. 10.1161/01.CIR.0000126824.12785.B6, 15123532.
12. Shi W, Wang NJ, Shih DM, Sun VZ, Wang X, Lusis AJ. Determinants of atherosclerosis susceptibility in the C3H and C57BL/6 mouse model: evidence for involvement of endothelial cells but not blood cells or cholesterol metabolism. Circ Res 2000, 86(10):1078-1084.
13. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258(5081):468-471. 10.1126/science.1411543, 1411543.
14. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14(1):133-140. 10.1161/01.ATV.14.1.133, 8274468.
15. Su Z, Li Y, James JC, Matsumoto AH, Helm GA, Lusis AJ, Shi W. Genetic linkage of hyperglycemia, body weight and serum amyloid-P in an intercross between C57BL/6 and C3H apolipoprotein E-deficient mice. Hum Mol Genet 2006, 15(10):1650-1658. 10.1093/hmg/ddl088, 16595606.
16. Tian J, Pei H, James JC, Li Y, Matsumoto AH, Helm GA, Shi W. Circulating adhesion molecules in apoE-deficient mouse strains with different atherosclerosis susceptibility. Biochem Biophys Res Commun 2005, 329(3):1102-1107. 10.1016/j.bbrc.2005.02.090, 15752767.
17. Dansky HM, Charlton SA, Barlow CB, Tamminen M, Smith JD, Frank JS, Breslow JL. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest 1999, 104(1):31-39. 10.1172/JCI6577, 408406, 10393696.
18. Lee SK, Opara EC, Surwit RS, Feinglos MN, Akwari OE. Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice. Pancreas 1995, 11(2):206-211. 10.1097/00006676-199508000-00016, 7479681.
19. McDuffie M, Maybee NA, Keller SR, Stevens BK, Garmey JC, Morris MA, Kropf E, Rival C, Ma K, Carter JD, Tersey SA, Nunemaker CS, Nadler JL. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes 2008, 57(1):199-208. 2993320, 17940120.
20. Clee SM, Yandell BS, Schueler KM, Rabaglia ME, Richards OC, Raines SM, Kabara EA, Klass DM, Mui ET, Stapleton DS, Gray-Keller MP, Young MB, Stoehr JP, Lan H, Boronenkov I, Raess PW, Flowers MT, Attie AD. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet 2006, 38(6):688-693. 10.1038/ng1796, 16682971.
21. Tian J, Pei H, Sanders JM, Angle JF, Sarembock IJ, Matsumoto AH, Helm GA, Shi W. Hyperlipidemia is a major determinant of neointimal formation in LDL receptor-deficient mice. Biochem Biophys Res Commun 2006, 345(3):1004-1009. 10.1016/j.bbrc.2006.04.180, 16712797.
22. Yuan Z, Pei H, Roberts DJ, Zhang Z, Rowlan JS, Matsumoto AH, Shi W. Quantitative trait locus analysis of neointimal formation in an intercross between C57BL/6 and C3H/HeJ apolipoprotein E-deficient mice. Circ Cardiovasc Genet 2009, 2(3):220-228. 10.1161/CIRCGENETICS.108.792499, 2733792, 19718279.
23. Li DS, Yuan YH, Tu HJ, Liang QL, Dai LJ. A protocol for islet isolation from mouse pancreas. Nat Protoc 2009, 4(11):1649-1652. 10.1038/nprot.2009.150, 19876025.
24. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985, 57(1):65-73. 10.1016/0021-9150(85)90138-8, 3841001.
25. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. Arterioscler Thromb 1994, 14(9):1480-1497. 10.1161/01.ATV.14.9.1480, 8068611.
26. Liao F, Andalibi A, deBeer FC, Fogelman AM, Lusis AJ. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993, 91(6):2572-2579. 10.1172/JCI116495, 443320, 8514869.
27. Liao F, Andalibi A, Qiao JH, Allayee H, Fogelman AM, Lusis AJ. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994, 94(2):877-884. 10.1172/JCI117409, 296170, 8040344.
28. Khanuja B, Cheah YC, Hunt M, Nishina PM, Wang DQ, Chen HW, Billheimer JT, Carey MC, Paigen B. Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc Natl Acad Sci USA 1995, 92(17):7729-7733. 10.1073/pnas.92.17.7729, 41219, 7644485.
29. Kooptiwut S, Zraika S, Thorburn AW, Dunlop ME, Darwiche R, Kay TW, Proietto J, Andrikopoulos S. Comparison of insulin secretory function in two mouse models with different susceptibility to beta-cell failure. Endocrinology 2002, 143(6):2085-2092. 10.1210/en.143.6.2085, 12021173.
30. Rossmeisl M, Rim JS, Koza RA, Kozak LP. Variation in type 2 diabetes--related traits in mouse strains susceptible to diet-induced obesity. Diabetes 2003, 52(8):1958-1966. 10.2337/diabetes.52.8.1958, 12882911.
31. Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A, Mijat V, Goldsworthy M, Moir L, Haynes A, Quarterman J, Freeman HC, Ashcroft FM, Cox RD. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 2005, 48(4):675-686. 10.1007/s00125-005-1680-z, 15729571.
32. Wencel HE, Smothers C, Opara EC, Kuhn CM, Feinglos MN, Surwit RS. Impaired second phase insulin response of diabetes-prone C57BL/6J mouse islets. Physiol Behav 1995, 57(6):1215-1220. 10.1016/0031-9384(95)00022-B, 7652047.
33. Seitz O, Schurmann C, Hermes N, Muller E, Pfeilschifter J, Frank S, Goren I. Wound healing in mice with high-fat diet- or ob gene-induced diabetes-obesity syndromes: a comparative study. Exp Diabetes Res 2010, 2010:476969. 3034929, 21318183.
34. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007, 56(9):2356-2370. 10.2337/db06-1650, 17579207.
35. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009, 24:325-331.
36. Bock T, Pakkenberg B, Buschard K. Genetic background determines the size and structure of the endocrine pancreas. Diabetes 2005, 54(1):133-137. 10.2337/diabetes.54.1.133, 15616020.
37. Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, Uno K, Hasegawa Y, Kanzaki M, Yamamoto TT, Ishibashi S, Oka Y. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007, 56(1):24-33. 10.2337/db06-0144, 17192461.
38. Karagiannides I, Abdou R, Tzortzopoulou A, Voshol PJ, Kypreos KE. Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J 2008, 275(19):4796-4809. 10.1111/j.1742-4658.2008.06619.x, 18754772.
39. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS?. Ann N Y Acad Sci 2010, 1212:59-77. 10.1111/j.1749-6632.2010.05838.x, 3057517, 21091714.
40. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. Islet-associated macrophages in type 2 diabetes. Diabetologia 2009, 52(8):1686-1688. 10.1007/s00125-009-1410-z, 19504085.
41. Heinonen SE, Merentie M, Hedman M, Makinen PI, Loponen E, Kholova I, Bosch F, Laakso M, Yla-Herttuala S. Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice. Cardiovasc Diabetol 2011, 10:59. 10.1186/1475-2840-10-59, 3141395, 21718508.
42. Fearnside JF, Dumas ME, Rothwell AR, Wilder SP, Cloarec O, Toye A, Blancher C, Holmes E, Tatoud R, Barton RH, Scott J, Nicholson JK, Gauguier D. Phylometabonomic patterns of adaptation to high fat diet feeding in inbred mice. PLoS One 2008, 3(2):e1668. 10.1371/journal.pone.0001668, 2244706, 18301746.